Kanjinti 150 mg Infusion: Uses, Safety and Key Facts
Quick summary: Kanjinti 150 mg powder for concentrate for solution for infusion contains trastuzumab, a monoclonal antibody used in HER2-positive cancers. It is given by intravenous infusion and requires specialist monitoring, especially for infusion...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: Kanjinti 150 mg powder for concentrate for solution for infusion contains trastuzumab, a monoclonal antibody used in HER2-positive cancers. It is given by intravenous infusion and requires specialist monitoring, especially for infusion reactions and heart-related safety checks.
Key point: Whether Kanjinti is suitable depends on confirmed HER2 testing and the treatment plan set by the oncology team.
Medical disclaimer: This article is for general information only and does not replace advice from an oncologist, pharmacist, or the official product leaflet. Treatment decisions, infusion schedules, and monitoring plans must be made by a qualified healthcare professional.
What is Kanjinti 150 mg powder for concentrate for solution for infusion?
Kanjinti is an antineoplastic monoclonal antibody that contains trastuzumab. It is used in cancers that overexpress the HER2 protein, including certain breast cancers and gastric cancers.
HER2 testing is needed before treatment to confirm whether the cancer is HER2-positive. Testing may be done using methods such as immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
How does Kanjinti work?
Kanjinti binds to the extracellular domain of the HER2 receptor. This helps block signals that support cancer cell growth and proliferation.
It may also help the immune system recognize and attack cancer cells through antibody-dependent cell-mediated cytotoxicity (ADCC).
- Targets the HER2 receptor
- Helps reduce growth signals in HER2-positive tumours
- May support immune-mediated destruction of cancer cells
What is Kanjinti used for?
Kanjinti is indicated for HER2-positive breast cancer, including early-stage and metastatic disease, and for HER2-positive gastric cancer.
Its use may include adjuvant treatment after surgery for early HER2-positive breast cancer and first-line treatment in metastatic HER2-positive breast cancer, depending on the treatment plan.
| Topic | What to know |
|---|---|
| Active ingredient | Trastuzumab |
| Route | Intravenous infusion |
| Main target | HER2 receptor |
| Typical use | HER2-positive breast and gastric cancers |
How is Kanjinti given?
Kanjinti is administered as an intravenous infusion by trained healthcare professionals. The infusion is monitored carefully, especially at the start of treatment, because infusion-related reactions can occur.
The original content notes that the infusion is started slowly and may be increased if tolerated. Exact infusion rates and schedules should be checked in the official leaflet or by the treating team, as they can vary by indication and protocol.
What dosage information is available?
The source content states that dosing may vary according to body weight and the cancer being treated. It also mentions an initial dose followed by a maintenance dose given every three weeks.
Because exact dosing depends on the treatment setting, the official product information and the oncology team should always be used for the final regimen.
What are the possible side effects?
Like other cancer medicines, Kanjinti can cause side effects. The original content highlights the following common effects:
- Fever and chills
- Headache
- Fatigue
- Nausea
- Diarrhoea
More serious concerns include possible effects on heart function. The article source notes that cardiac monitoring is important, especially in people with a history of heart disease.
What precautions should be considered?
Before and during treatment, healthcare professionals may consider several safety points:
- Heart monitoring during treatment
- Review of any existing heart conditions
- Discussion of pregnancy and contraception precautions
- Avoidance of breastfeeding during therapy, if advised by the treating team
- Review of all other medicines to check for possible interactions
Patients should always tell their oncology team about any new symptoms, including breathlessness, swelling, chest discomfort, or fever during infusion.
Frequently asked questions
▸ What is the active ingredient in Kanjinti?
The active ingredient is trastuzumab.
▸ What cancers is Kanjinti used for?
The source content states that it is used for HER2-positive breast cancer and HER2-positive gastric cancer.
▸ Why is HER2 testing important?
HER2 testing helps confirm whether the cancer is HER2-positive and whether trastuzumab-based treatment may be appropriate.
▸ How is Kanjinti administered?
It is given as an intravenous infusion under specialist supervision.
▸ What side effects should be watched for?
The source content mentions fever, chills, headache, fatigue, nausea, diarrhoea, and possible heart-related effects.
▸ Where can I confirm the exact dose and infusion schedule?
Check the official product leaflet or ask the prescribing oncology team or pharmacist, because the regimen depends on the indication and treatment protocol.
Safety reminder
If you are receiving Kanjinti, seek urgent medical advice for severe infusion reactions, breathing problems, chest symptoms, or any sudden change in how you feel. Always follow the monitoring plan set by your healthcare team.
Related note
The original content also mentioned etoposide and trastuzumab in general. These are different medicines with different uses, so product names and formulations should always be checked carefully before any treatment discussion.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.